VYGR
Income statement / Annual
Last year (2023), Voyager Therapeutics, Inc.'s total revenue was $250.01 M,
an increase of 511.16% from the previous year.
In 2023, Voyager Therapeutics, Inc.'s net income was $132.33 M.
See Voyager Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$250.01 M
|
$40.91 M
|
$37.42 M
|
$171.13 M
|
$104.39 M
|
$7.62 M
|
$10.14 M
|
$14.22 M
|
$17.33 M
|
$0.00
|
Cost of Revenue |
$4.44 M |
$6.19 M |
$73.79 M |
$108.75 M |
$119.74 M |
$64.91 M |
$62.26 M |
$42.25 M |
$27.68 M |
$8.90 M |
Gross Profit |
$245.57 M |
$34.72 M |
-$36.37 M |
$62.38 M |
-$15.34 M |
-$57.29 M |
-$52.13 M |
-$28.03 M |
-$10.35 M |
-$8.90 M |
Gross Profit Ratio |
0.98 |
0.85 |
-0.97 |
0.36 |
-0.15 |
-7.52 |
-5.14 |
-1.97 |
-0.6 |
0 |
Research and Development
Expenses |
$87.73 M
|
$60.76 M
|
$73.79 M
|
$108.75 M
|
$119.74 M
|
$64.91 M
|
$62.26 M
|
$42.25 M
|
$27.68 M
|
$8.90 M
|
General & Administrative
Expenses |
$35.82 M
|
$30.98 M
|
$37.25 M
|
$34.99 M
|
$36.34 M
|
$33.81 M
|
$19.74 M
|
$13.27 M
|
$9.91 M
|
$5.47 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$35.82 M
|
$30.98 M
|
$37.25 M
|
$34.99 M
|
$36.34 M
|
$33.81 M
|
$19.74 M
|
$13.27 M
|
$9.91 M
|
$5.47 M
|
Other Expenses |
$3,000.00 |
$4.45 M |
$2.42 M |
$7.70 M |
$8.08 M |
$2.63 M |
$1.17 M |
$1.16 M |
-$9.42 M |
$0.00 |
Operating Expenses |
$123.55 M |
$91.74 M |
$111.03 M |
$143.74 M |
$156.07 M |
$98.71 M |
$82.00 M |
$55.52 M |
$37.59 M |
$14.37 M |
Cost And Expenses |
$127.99 M |
$91.74 M |
$111.03 M |
$143.74 M |
$156.07 M |
$98.71 M |
$82.00 M |
$55.52 M |
$37.59 M |
$14.37 M |
Interest Income |
$11.72 M |
$1.79 M |
$390,000.00 |
$1.66 M |
$6.46 M |
$0.00 |
$1.23 M |
$0.00 |
$0.00 |
$0.00 |
Interest Expense |
$0.00 |
$1.79 M |
-$390,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$976,000.00 |
$332,000.00 |
$0.00 |
Depreciation &
Amortization |
$4.44 M
|
$6.19 M
|
$5.17 M
|
$3.82 M
|
$2.77 M
|
$2.12 M
|
$1.60 M
|
$612,000.00
|
$600,000.00
|
$184,000.00
|
EBITDA |
$126.46 M
|
-$50.84 M
|
-$73.62 M
|
$31.20 M
|
-$51.68 M
|
-$91.10 M
|
-$71.86 M
|
-$41.30 M
|
-$20.25 M
|
-$14.18 M
|
EBITDA Ratio |
0.51 |
-1.24 |
-1.97 |
0.18 |
-0.5 |
-11.96 |
-7.09 |
-2.9 |
-1.17 |
0 |
Operating Income Ratio
|
0.49
|
-1.24
|
-1.97
|
0.16
|
-0.5
|
-11.96
|
-7.09
|
-2.9
|
-1.17
|
0
|
Total Other
Income/Expenses Net |
$11.72 M
|
$4.45 M
|
$2.42 M
|
$9.36 M
|
$8.08 M
|
$2.63 M
|
$1.17 M
|
$1.16 M
|
-$9.42 M
|
-$1.95 M
|
Income Before Tax |
$133.74 M |
-$46.39 M |
-$71.20 M |
$36.74 M |
-$43.60 M |
-$88.47 M |
-$70.70 M |
-$40.14 M |
-$29.67 M |
-$16.32 M |
Income Before Tax Ratio
|
0.53
|
-1.13
|
-1.9
|
0.21
|
-0.42
|
-11.61
|
-6.98
|
-2.82
|
-1.71
|
0
|
Income Tax Expense |
$1.41 M |
$16,000.00 |
-$5.17 M |
-$1.66 M |
-$2.77 M |
-$180,000.00 |
-$1.60 M |
$52,000.00 |
-$600,000.00 |
$0.00 |
Net Income |
$132.33 M |
-$46.41 M |
-$66.03 M |
$36.74 M |
-$40.83 M |
-$88.29 M |
-$70.70 M |
-$40.19 M |
-$29.67 M |
-$16.32 M |
Net Income Ratio |
0.53 |
-1.13 |
-1.76 |
0.21 |
-0.39 |
-11.59 |
-6.98 |
-2.83 |
-1.71 |
0 |
EPS |
3.08 |
-1.21 |
-1.75 |
0.99 |
-1.14 |
-2.75 |
-2.64 |
-1.59 |
-7.08 |
-1.11 |
EPS Diluted |
2.97 |
-1.21 |
-1.75 |
0.98 |
-1.14 |
-2.75 |
-2.64 |
-1.59 |
-7.08 |
-1.11 |
Weighted Average Shares
Out |
$43.02 M
|
$38.36 M
|
$37.67 M
|
$37.13 M
|
$35.90 M
|
$32.07 M
|
$26.80 M
|
$25.30 M
|
$4.19 M
|
$14.71 M
|
Weighted Average Shares
Out Diluted |
$44.57 M
|
$38.36 M
|
$37.67 M
|
$37.35 M
|
$35.90 M
|
$32.07 M
|
$26.80 M
|
$25.30 M
|
$4.19 M
|
$14.71 M
|
Link |
|
|
|
|
|
|
|
|
|
|